MGC Pharmaceuticals Enters Partnership with Sciensus Rare for Distribution of Cannabinoids to Treat Refractory Epilepsy, Dementia and Alzheimer’s in the EU and UK
Ryan Allway April 5th, 2022 News, Top News LONDON, April 5, 2022 /PRNewswire/ — MGC Pharmaceuticals Ltd. (LSE: MXC, ASX: MXC, OTC:MGCLF), a European based bio-pharma company specializing in the production and development of phytomedicines, has signed an exclusive distribution agreement with Sciensus Rare, a part of UK health care group, Sciensus, for the distribution... Read more
( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )